Abstract:
Objective
To investigate the clinical efficacy of montelukast combined with vitamin C in the treatment of allergic purpura in children.
Methods
From November 2014 to January 2010, 86 children with Henoch-Schonlein purpura were hospitalized and treated in the Department of Nephrotic Rheumatology, Hunan Children 's Hospital, and they were randomly divided into control group(43 cases) and observation group(43 cases). The control group was treated with montelukast orally taken. The observation group was treated with vitamin C in addition to monteleukast, and the treatment lasted for 7 days. The levels of plasma cytokine(interleukin 6, interleukin 8, tumor necrosis factor α) and adverse effects were compared between the two groups after treatment.
Results
The total effective rate was 95.35% (41/43) in the observation group, which was significantly higher than that in the control group (81.40%, 35/43), and the difference was statistically significant(P<0.05). After treatment, the level of interleukin 6,interleukin 8 and tumor necrosis factorα was significantly lower in the observation group than in the control group(P<0.05). The incidence of adverse events in the observation group was 2.33%(1/43),which was significantly lower than that of the control group(18.60%,8/43)(P<0.05).
Conclusion
The combination therapy of montelukast with vitamin C for children with Henoch-Schonlein purpura is effective and safe, with lower adverse reaction incidence. It is worthy of clinical application.

Key words: Allergic purpura, Montelukast, Vitamin C, Combination therapy, Children